Ticker Watch

Taylor, Marisa
April 2007
Red Herring;4/30/2007, Vol. 4 Issue 16, p33
Trade Publication
The article presents information on the experimental drug AGI-1067, being tested by Alpharetta, Georgia-based biotechnology company Atherogenics, to treat heart disease. The drug aimed to curb inflammatory response, and pharmaceutical giant AstraZeneca went into partnership to push it along. Scientists and analysts were intrigued, and they waited in anticipation for results from clinical trials. AGI-1067 could be the future of cardiovascular medicine, after all. But then late-phase trials of AGI-1067 failed to reduce incidence of heart attack, cardiovascular death, stroke, unstable angina, and other ailments. And analysts tore into the results, putting Atherogenic's stock in a freefall.


Related Articles

  • AstraZeneca: further setbacks ARISE.  // PharmaWatch: Monthly Review;May2007, Vol. 6 Issue 5, p11 

    The article focuses on the failure of the cardiovascular agent AGI-1067 in the phase III ARISE clinical trial. The drug is manufactured by AstraZeneca PLC. The trial was conducted by AstraZeneca and AtheroGenics Inc. to evaluate the safety of the drug in the treatment of patients with acute...

  • Treatment of heart failure. Mead, Mike // Practice Nurse;5/14/2004, Vol. 27 Issue 9, p44 

    Highlights clinical trials that provided the evidence base for diagnosis and therapy for heart failure. Percentage of the population affected by heart failure; Data on the Studies of Left Ventricular Dysfunction trial using angiotensin converting enzyme inhibitors; Benefits using angiotensin...

  • Treatment of Heart Failure with Spironolactone – Trial and Tribulations. McMurray, John J.V.; O'Meara, Eileen // New England Journal of Medicine;8/5/2004, Vol. 351 Issue 6, p526 

    The article presents an editorial regarding a clinical trial by Juurlink and colleagues in this issue of the journal, titled the Randomized Aldactone Evaluation Study (RALES), which looked at the treatment of heart failure with spironolactone. The clinical trial showed a low incidence of adverse...

  • Impulse completes enrollment in FIX-HF-5 trial.  // Medical Technology & Devices Week;6/11/2007, Vol. 5 Issue 24, p5 

    The article reports the completion of the patient enrollment in the Fix Heart Failure 5 (FIX-HF-5) study of Impulse Dynamics for its Optimizer III device. Based on the article, the study is the largest randomized clinical trial of Impulse to date and is aimed to evaluate the safety and efficacy...

  • Stem Cell Therapy Linked to Heart Failure Recovery.  // BioPharm International;Jul2005, Vol. 18 Issue 7, p12 

    Reports that a clinical trial has revealed that advanced heart failure patients treated with stem cell therapy show an average 41 percent improvement in their hearts' pumping efficiency. Data points of 10 patients who had received injections of stem cells into their hearts; Increase in the...

  • Adjunctive treatment with eplerenone reduced 30 day all cause mortality in acute myocardial infarction. Pitt, B.; White, H.; Nicolau, J. // Evidence Based Medicine;Feb2006, Vol. 11 Issue 1, p14 

    The article reports on a study to determine whether adjunctive treatment with eplerenone can decrease morbidity and mortality better than placebo in patients with acute myocardial infarction (AMI) with left ventricular systolic dysfunction (LVSD) and heart failure. A randomized placebo...

  • Clinical trials update: Highlights of the Scientific Sessions of Heart Failure 2001, a meeting of the Working Group on Heart Failure of the European Society of Cardiology. CONTAK-CD, CHRISTMAS, OPTIME-CHF. Thackray, Simon; Coletta, Alison; Jones, Peter; Dunn, Anita; Clark, Andrew L.; Cleland, John G.F. // European Journal of Heart Failure;Aug2001, Vol. 3 Issue 4, p491 

    This article continues a series of reports summarising recent research developments pertinent to the topic of heart failure. This is a summary of presentations made at Scientific Sessions of Heart Failure 2001, a meeting of the Working Group on Heart Failure of the European Society of...

  • Clinical brief.  // New Zealand Doctor;6/2/2004, p21 

    Reports on a research which tested a cardiac resynchronization therapy device for heart failure patients, which was published in the 2004 issue of "New England Journal of Medicine." Classification of clinical trial patients; Implications of the study's findings for heart failure treatment.

  • Beneficios clínicos de la resincronización cardiaca. Guevara-Valdivia, Milton E. // Archivos de Cardiología de México;2009 Supplement 2, Vol. 79 Issue 5, p71 

    Despite the improvement in pharmacologic treatment of heart failure, many patients continue to have severe persistent symptoms, and their prognosis remains poor. One of the most recent advances in heart failure management is the concept of cardiac resynchronization therapy (CRT). Large clinical...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics